

- 821 New York City Department of Health Response to Terrorist Attack
- 822 Update: Influenza Activity United States and Worldwide
- 826 Progress Toward Poliomyelitis Eradication — Angola, Democratic Republic of Congo, Ethiopia, and Nigeria
- 830 Weekly Update: West Nile Virus Activity — United States
- 831 Notices to Readers

Notice to Readers

MORBIDITY AND MORTALITY

WEEKLY REPORT

New York City Department of Health Response to Terrorist Attack, September 11, 2001

In response to two jet aircraft crashing into and causing the collapse of the 110storied World Trade Center (WTC) towers and the subsequent destruction of nearby portions of lower Manhattan, the New York City Department of Health (NYCDOH) immediately activated its emergency response protocol, including the mobilization of an Emergency Operations Center. Surveillance, clinical, environmental, sheltering, laboratory, management information systems, and operations were among the preestablished emergency committees. Because of its proximity to the WTC site, an emergency clinic was established at NYCDOH for triage and treatment of injured persons. NYCDOH focused its initial efforts on assessing the public health and medical impact of the attack and the resources needed to respond to it such as the care and management of large numbers of persons injured or killed by the crash; subsequent fire and building collapse; the health and safety of rescue workers; the environmental health risks (e.g., asbestos, smoke, dust, or chemical inhalation); other illnesses related to the disruption of the physical infrastructure (e.g., waterborne and foodborne diseases); and mental health concerns. Despite the evacuation and relocation of NYCDOH's headquarters, the department continued essential public health services, including death registration.

A rapid assessment conducted by NYCDOH during the first 24 hours after the incident indicated that most emergency department (ED) visits were for minor injuries; approximately 10%–15% of ED patients were admitted and few deaths occurred. Hospital bed and staff capacity was adequate.

Following the incident, NYCDOH prioritized four surveillance activities: 1) in collaboration with the Greater New York Hospital Association, an ongoing assessment of hospital staffing and equipment needs, and cumulative numbers of incident-related ED visits and hospital admissions; 2) an epidemiologic assessment of the types of injuries seen during the first 48 hours after the attack at one tertiary referral hospital and the four EDs closest to the crash site where the largest number of incident-related cases presented; 3) prospective surveillance of illnesses and injuries among rescue workers evaluated at the four hospitals and Disaster Medical Assistance Team triage units located at the crash site; and 4) active surveillance in EDs for specified clinical syndromes to identify unusual disease manifestations or clusters associated with these incidents, including those syndromes that could result from the release of a biologic agent. To assist NYCDOH with

U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES

Terrorist Attack — Continued

syndromic surveillance, CDC Epidemic Intelligence Service officers have been stationed at EDs in 15 sentinel hospitals distributed throughout the five New York City boroughs. Other NYCDOH activities included an already existing syndromic surveillance system to monitor 911 emergency calls. No unusual patterns of illness have been identified. NYCDOH also conducted laboratory testing of environmental samples and did not find evidence of a biologic agent release.

Air quality, safety of the municipal water supply, restaurant safety and rodent control, and other environmental conditions in the area continue to be monitored by NYCDOH, in collaboration with local, state, and federal agencies, to ensure the health and safety of workers at the site and residents in the immediate vicinity. Frequent alerts are sent by broadcast facsimile and electronic mail to advise metropolitan New York health-care providers of ongoing public health concerns related to the aftermath of the attack. Advisories have been developed to address the public's concerns about such issues as asbestos exposure in collapsed buildings, decomposing bodies, and managing emotional trauma. Working with the American Red Cross, NYCDOH school health program has provided nursing services and physician consultations to Red Cross shelters. The shelters serve families and persons displaced by the incident and provide respite to rescue workers. NYCDOH nurses provide nursing assessments, first-aid services, and medical referrals when needed.

In response to events in lower Manhattan and the related attack on the Pentagon in Washington, DC, the Federal Response Plan was activated. The U.S. Department of Health and Human Services (DHHS) deployed federal resources under Emergency Support Function #8 (Health and Medical) to augment the state and local medical response. A shipment of intravenous supplies, airway supplies, emergency medication, bandages and dressings, and other materials arrived in New York City the night of September 11; this was the first emergency mobilization of the National Pharmaceutical Stockpile. NYCDOH and the health department in Washington, DC, also obtained adequate supplies of tetanus vaccine from vaccine manufacturers. CDC has sent epidemiologists, occupational health specialists, industrial hygienists, and other public health professionals to supplement local efforts. Information about federal support of the local public health response is available from DHHS at ">http://www.hhs.gov>.

Update: Influenza Activity — United States and Worldwide, May–September 2001

During October 2000–May 2001, influenza A (H1N1), A (H3N2), and B viruses were identified in the Northern Hemisphere. Influenza A (H1N1) and B viruses circulated widely; influenza A (H3N2) viruses were reported infrequently and were not associated with widespread outbreaks in any country during October 2000–May 2001. Since May 2001, influenza A (H1N1) and B viruses have predominated in Asia and Oceania; influenza A (H3N2) and B viruses have predominated in Africa and South America. This report summarizes influenza activity in the United States* (*1*) and worldwide during May–September 25; influenza A (H1N1), A (H3N2), and B viruses continued to circulate worldwide and were associated with mild to moderate levels of activity. This activity underscores the need to follow the recommendations of the Advisory Committee on Immunization Practices (ACIP) (*2,3*) for the timely vaccination of persons at high risk for influenza-related complications.

*The four components of the influenza surveillance system have been described (1).

United States

Influenza B viruses were reported more frequently than influenza A viruses during May 2001. Unsubtyped influenza A viruses were reported from Alaska and Missouri during June; influenza A (H1N1) viruses were reported from one case in Michigan and one case in Texas in June and July, respectively. In Hawaii, an influenza A (H3N2) virus was isolated from one case during June and two A (H1N1) viruses were isolated in July and August. Influenza B viruses were isolated in Hawaii each month during May–July.

Worldwide

During May–September 25, influenza A (H1N1) and B viruses circulated in Asia and Oceania; influenza A (H3N2) viruses were identified less frequently than influenza A (H1N1) and B viruses and were not associated with widespread activity. In Africa, influenza A (H3N2) viruses were reported from Senegal and South Africa, and influenza B viruses were reported from Mauritius and South Africa. In South America, influenza A (H3N2) and B viruses circulated widely, and influenza A (H1N1) viruses have been identified less frequently. Influenza A (H3N2) viruses predominated in Argentina and Chile; in Brazil and Paraguay, influenza type B viruses were reported more frequently than influenza type A viruses. Both influenza A (H3N2) and B viruses also were reported from Uruguay. In Canada, influenza A and B viruses were identified during May–August.

Isolate Analysis

The WHO Collaborating Center for Surveillance, Epidemiology, and Control of Influenza at CDC analyzes isolates from laboratories worldwide. This report describes the antigenic characteristics of influenza isolates collected during May–September 25, including isolates from the Northern Hemisphere and Southern Hemisphere. Of the 25 influenza A (H1N1) isolates antigenically characterized, 24 (96%) were similar to A/New Caledonia/20/99, the H1N1 component of the 2001–02 influenza vaccine, and one (4%) showed reduced titers with A/New Caledonia/20/99 antisera. Of the 25 influenza A (H1N1) isolates, six were from Asia, 10 were from Oceania, eight were from South America, and one was from the United States. Of the 67 influenza A (H3N2) viruses antigenically characterized, 61 (91%) were similar to A/Panama/2007/99, the H3N2 component of the 2001–02 influenza vaccine, and six (9%) showed reduced titers with A/Panama/2007/99 antisera. Of the 67 influenza A (H3N2) viruses, 17 were from Asia, two were from Oceania, 47 were from South America, and one was from the United States.

Circulating influenza B viruses can be divided into two antigenic and genetic groups represented by B/Yamagata/16/88 and B/Victoria/2/87 reference strains (Table 1). B/Victoria/2/87 group viruses circulated widely before 1991; however, during 1991–2000, these viruses were identified only in Asia (China, Hong Kong/China, Japan, Singapore, Taiwan, and Thailand). Since 1990, B/Yamagata/16/88 group viruses have circulated worldwide. The recommended influenza B vaccine strain, B/Sichuan/379/99, belongs to the B/Yamagata/16/88 group. Most of the viruses in the B/Victoria/2/87 group are represented by the reference strain B/Hong Kong/22/2001. Of the 54 antigenically characterized influenza B viruses collected worldwide during May–September 25, 37 (69%) belong to the B/Yamagata/16/88 group, and 17 (31%) belong to the B/Victoria/2/87 group. Of 37 B/Yamagata/16/88 group viruses, 35 (95%) were similar to recommended vaccine strain B/Sichuan/379/99, and two (5%) showed reduced titers with B/Sichuan/379/99 antisera. These B/Sichuan/379/99-like viruses were from the United States (Hawaii and Massachusetts), Asia (China, Hong Kong/China, Japan, and Thailand), South America

Influenza Activity — Continued

	Antisera									
Viral antigen	B/Sichuan/ 379/99	B/Victoria/ 504/2000	B/Hong Kong/ 6/2001	B/Hong Kong/ 22/2001						
B/Yamagata/16/88 group viruses										
B/Sichuan/379/99	320	2560	20	10						
B/Victoria/504/2000	320	2560	10	<10						
B/Victoria/2/87 group viruses										
B/Hong Kong/6/2001	<10	20	1280	640						
B/Hong Kong/22/2001	<10	10	640	640						

TABLE 1. Hemagglutination-inhibition titers of influenza B viruses* — United
States and worldwide, May-September 25, 2001

* A fourfold difference in hemagglutination-inhibition titer between two viruses usually indicates antigenic variation between viruses.

(Argentina, Brazil, Chile, and Costa Rica) and Oceania (Australia and New Zealand). The influenza B/Victoria/2/87 group viruses collected during May–September 25 were isolated in Hawaii and Hong Kong/China. During March, one B/Victoria/2/87 group virus was reported in Canada from a patient who recently had traveled in Asia. No B/Victoria/2/87 group viruses have been identified in Europe, Oceania, or South America.

Reported by: World Health Organization National Influenza Centers, Communicable Diseases, Surveillance and Response, World Health Organization, Geneva, Switzerland. A Hay, PhD, WHO Collaborating Center for Reference and Research on Influenza, National Institute for Medical Research, London, England. I Gust, MD, A Hampson, WHO Collaborating Center for Reference and Research on Influenza, Parkville, Australia. M Tashiro, MD, WHO Collaborating Center for Reference and Research on Influenza, National Institute of Infectious Diseases, Tokyo, Japan. R Ueki, S Nagaue, L Muus, G Kunimoto, Virology Section, State Laboratories Div; T Tom, MS, M leong, MPH, Epidemiology Br, Hawaii Dept of Health, Honolulu. WHO collaborating laboratories. National Respiratory and Enteric Virus Surveillance System laboratories. WHO Collaborating Center for Surveillance, Epidemiology and Control of Influenza, Influenza Br and Respiratory and Enteric Viruses Br, Div of Viral and Rickettsial Diseases, National Center for Infectious Diseases, CDC.

Editorial Note: Influenza A (H1N1), A (H3N2), and B viruses circulated during the winter in the Southern Hemisphere (May–mid-September) and summer (May–mid-September) in the Northern Hemisphere. The identification of influenza cases and sporadic influenza outbreaks during summer and fall are not unusual. From June through mid-September, few influenza isolates were identified in Alaska, Canada, and the continental United States. Most of the viruses identified were influenza type A; two influenza A viruses were subtyped (H1N1). The most frequently isolated influenza viruses in Hawaii were influenza B viruses and both of the antigenic groups have been identified. Most of the viruses isolated worldwide since May are well matched to the current vaccine strains.

For the 2001–02 season in the Northern Hemisphere, the type(s) and subtype(s) of influenza virus that will circulate and the onset, peak, and severity of disease activity cannot be predicted. The optimal time for persons at increased risk for influenza-related complications to receive annual influenza vaccination is October and November; vaccination of other persons should continue through December and later as long as vaccine is available (*2,3*). The three influenza vaccine manufacturers distributing in the United States are expected to produce and distribute approximately 79 million doses combined.

Influenza Activity — Continued

Distribution of 44.6 million doses (56% of projected season totals) may be delayed until the end of October; the remaining 35 million doses are expected to be distributed in November and December.

During July 2001, ACIP issued recommendations to address an anticipated delay in influenza vaccine availability (3). The primary recommendations for health-care providers were 1) to target vaccine available in September and October to persons at increased risk for influenza complications and to health-care workers, 2) beginning in November, also to offer vaccine to contacts of high-risk persons, healthy persons aged 50–64 years, and others who want to reduce their risk for influenza, and 3) to continue vaccinating patients, especially those at high risk and in other target groups, in December and throughout the influenza season as long as vaccine is available. Recommendations for influenza vaccine to worksites, where campaigns primarily vaccinate healthy persons, and 2) to process orders so that all providers who have ordered vaccine receive some early season vaccine. Previously, ACIP extended the recommended optimal time for vaccination from October through the end of November (2).

Each February, the World Health Organization (WHO) recommends influenza virus strains for inclusion in the following season's Northern Hemisphere influenza vaccine (4). The regulatory authorities in each country then determine the actual viruses to be used for vaccine production. In the United States, the Food and Drug Administration's Vaccines and Related Biological Products Advisory Committee is responsible for the selection of vaccine strains to be used by U.S. vaccine manufacturers. The regulatory authorities in a country frequently will substitute an antigenically equivalent virus for one or more of the WHO recommended viruses because of better growth or processing properties. For the 2001–02 influenza season, WHO recommended A/New Caledonia/20/99-like (H1N1), A/Moscow/10/99-like (H3N2), and B/Sichuan/379/99-like viruses for inclusion in the Northern Hemisphere influenza vaccine (4). Influenza vaccines sold in North America will use A/New Caledonia/20/99 for the H1N1 component and the antigenically equivalent stains of A/Panama/2007/99 (H3N2) for the A/Moscow/10/99-like strain and B/Johannesburg/5/99, B/Victoria/504/2000, or B/Guangdong/120/2000 for the B/Sichuan/379/99-like strain.

Updated information about vaccine availability is available at <http://www.cdc.gov/ nip/flu/>. This site also has patient education materials, suggestions on establishing a patient reminder/recall system, and other information that may assist providers in distributing influenza vaccine. Formal surveillance for influenza in the United States and reporting by CDC is conducted during October–May. This information is updated weekly and is available through CDC's voice information system, telephone (888) 232-3228, the fax information system, telephone (888) 232-3299, by requesting document number 361100, or at <http://www.cdc.gov/ncidod/diseases/flu/weekly.htm>.

References

- 1. CDC. Influenza activity—United States, 1999–2000 season. MMWR 1999;48:1039–42.
- 2. CDC. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR 2001;50(no. RR-4).
- 3. CDC. Delayed influenza vaccine availability for 2001–02 season and supplemental recommendations of the Advisory Committee on Immunization Practices. MMWR 2001;50:582–5.
- 4. World Health Organization. Recommended composition of influenza virus vaccines for use in the 2001–02 season. Wkly Epidemiol Rec 2001;76:58–61.

Progress Toward Poliomyelitis Eradication — Angola, Democratic Republic of Congo, Ethiopia, and Nigeria, January 2000–July 2001

In 1988, the World Health Assembly, governing body of the World Health Organization (WHO), resolved to eradicate poliomyelitis globally by 2000 (1). In the African Region (AFR), WHO member countries began to implement polio eradication strategies in 1995. Although rapid progress has occurred in much of eastern and southern Africa, wild poliovirus transmission continues to occur in four priority countries: Angola, Democratic Republic of Congo (DR Congo), Ethiopia, and Nigeria (2). This report summarizes progress toward polio eradication in Angola, DR Congo, Ethiopia, and Nigeria during January 2000–July 2001, and indicates that 11 of 12 cases of wild poliovirus in AFR were identified in these priority countries during January–July 2001 (Figure 1).




FIGURE 1. Location of wild poliovirus cases, by type — African Region (AFR), World Health Organization, January–July 2001

Routine Vaccination

The four priority countries have reported low rates of routine coverage with three doses of oral polio vaccine (OPV3). In 2000, reported OPV3 coverage among infants was 42% in DR Congo, 42% in Ethiopia, 38% in Nigeria, and 33% in Angola.

Supplemental OPV Vaccination Activities

Supplemental OPV vaccination activities were conducted in all four priority countries in 2000 and 2001. In Angola, three rounds of national immunization days (NIDs)* were conducted in June, July, and August 2000 with an additional subnational immunization day (SNID)[†] conducted just before and after NIDs in accessible areas. Access to rebelcontrolled areas could not be secured, and approximately 100,000 children aged <5 years did not receive OPV. In DR Congo, three rounds of NIDs were conducted in July, August, and September 2000. A house-to-house strategy was implemented for the first time in one third of the country, excluding some rebel-controlled areas. Similar to Angola, monitoring of NIDs in DR Congo indicated that 3%-10% of houses were not visited, suggesting that children were not reached even in accessible areas. Ethiopia conducted two rounds of SNIDs in March and April 2000 and two rounds of NIDs in November and December 2000. Nigeria conducted four rounds of NIDs in May and June and October and November 2000. During October–November 2000, NIDs in Nigeria were synchronized with those of 15 other countries in west and central Africa with substantial crossborder vaccination activities, high political commitment, and community mobilization (3). NIDs and SNIDs in the four priority countries reported >90% vaccination coverage by round in accessible areas, reaching approximately 73 million children aged <5 years with OPV.

In 2001, SNIDs were conducted in Angola and Ethiopia during February–April 2001, using the house-to-house strategy. Three rounds of NIDs were conducted in Nigeria in January, May, and June 2001. The first two rounds of the central African synchronized NIDs were completed in Angola, Gabon, Congo (Brazzaville), and DR Congo during July–August 2001. Preliminary results indicate that approximately 16 million children were vaccinated during synchronized NIDs, including 11,898,767 in DR Congo.

Acute Flaccid Paralysis (AFP) Surveillance

The goal of AFP surveillance is to detect circulating polioviruses and provide data for developing appropriate supplementary vaccination strategies. AFP surveillance is evaluated by two key indicators: sensitivity of reporting (target: nonpolio AFP rate of \geq 1 case per 100,000 children aged <15 years) and completeness of specimen collection (target: two adequate stool specimens[§] from \geq 80% of all persons with AFP).

From January 2000 through July 2001, the annualized nonpolio AFP rate increased from 0.7 to 3.8 in Nigeria (Table 1). In DR Congo, the annualized nonpolio AFP rate increased from 2.3 in 2000 to 9.0 in 2001 but remained relatively stable in Angola (1.2 in 2001) and Ethiopia (0.6 in 2001). The percentage of adequate stool specimens collected from persons with AFP increased substantially for DR Congo and Nigeria, increased for

^{*}Mass campaigns over a period of days to weeks, in which two doses of OPV are administered to all children (usually aged <5 years), regardless of previous vaccination history, with an interval of 4–6 weeks between doses.

[†] Same procedure as NIDS but in a smaller area.

[§] Two stool specimens collected at least 24 hours apart within 14 days from onset of paralysis and shipped adequately to the laboratory.

Poliomyelitis Eradication — Continued

			2000			January–July 2001						
Country	No. AFP cases	Non- polio AFP rate*	Persons with AFP with adequate specimens [†] (%)	Polio cases (wild virus confirmed)		No. AFP cases	Non- polio AFP rate	Persons with AFP with adequate specimens (%)	Polio cases (wild virus confirmed)			
Angola	217	1.6	54	119	(55)	63	1.2	52	20	(0)		
DR Congo [§]	1078	2.3	35	513	(28)	1312	9.0	72	0			
Ethiopia	345	0.7	45	144	(3)	170	0.6	53	69	(1)		
Nigeria	978	0.7	37	637	(28)	1090	3.8	64	10	(10)		
Total	2618			1413	(114)	2635			99	(11)		

TABLE 1. Number of reported cases of acute flaccid paralysis (AFP),
nonpoliomyelitis AFP rates, and confirmed polio cases in priority countries —
African Region, World Health Organization, January 2000–July 2001

* Per 100,000 children aged <15 years.

⁺ Two stool specimens collected at an interval of at least 24 hours within 14 days of onset of paralysis and adequately shipped to the laboratory.

[§] Democratic Republic of Congo.

Ethiopia, and decreased for Angola. In all four priority countries, the percentage of adequate stool specimens remained <80%. The geographic distribution of reported AFP cases is proportionate to population density in Ethiopia and Nigeria but is skewed to accessible areas in Angola and DR Congo.

Polio Incidence

Despite surveillance improvements in these countries, no wild poliovirus has been detected in Angola and DR Congo in 2001. Both countries contain inaccessible areas because of civil conflict. Only 10 cases of wild poliovirus have been isolated in Nigeria in 2001. In Ethiopia, wild poliovirus was isolated from a child residing in an area where poliovirus was detected in 1999 and 2000, suggesting that wild poliovirus transmission has continued in 2001.

The polio laboratory network for AFR includes 15 national polio laboratories, three of which serve as regional reference laboratories (Central African Republic, Ghana, and South Africa). All stool specimens collected in the four countries are processed in WHO accredited laboratories. Angola is served by the regional laboratory in South Africa. DR Congo, Ethiopia, and Nigeria are served by their national laboratories. As of July 8, 2001, DR Congo, Ethiopia, and Nigeria submitted 4040 stool specimens. Of 3402 specimens with completed test results to date, 2865 (84%) were negative and 382 (11%) contained nonpolio enteroviruses (NPEV). An NPEV rate of 10%–20% indicates good quality of stool condition on arrival in the laboratory.

Reported by: Expanded Program on Immunization, World Health Organization Regional Office for Africa, Harare, Zimbabwe. Vaccines and Biologicals Dept, World Health Organization, Geneva, Switzerland. Respiratory and Enteric Viruses Br, Div of Viral and Rickettsial Diseases, National Center for Infectious Diseases; Vaccine Preventable Disease Eradication Div, National Immunization Program, CDC.

Poliomyelitis Eradication — Continued

Editorial Note: During January–July 2001, only three of 46 countries in AFR (Nigeria, Ethiopia, and Mauritania) reported wild poliovirus isolates; however, Angola and DR Congo contain inaccessible areas because of civil conflict. The incidence of wild poliovirus decreased throughout the region from 61 cases reported in AFR as of August 28, 2000, to 12 cases as of August 28, 2001 (WHO, unpublished data, 2001). These achievements resulted from improvements in surveillance and supplemental immunization activities (SIAs) during the preceding 18 months.

Interrupting the remaining chains of wild poliovirus transmission through high-quality SIAs is critical for AFR priority countries during 2001–2002. In Angola, improving SIAs in accessible areas and strengthening the AFP surveillance system will enable identification of areas with poliovirus circulation. The quality and geographic extent of SIAs in Angola need to be improved, especially mapping, marking of houses, record keeping, supervising, using of independent monitors, and social mobilizing. Access to children residing in rebel-controlled areas remains a challenge. In DR Congo, the high AFP rate in 2001 raises a concern of reporting of AFP cases that may not meet the case definition. The NPEV isolation rate of 14.5% for the first half of 2001 suggests that the reverse cold chain that transports these samples to the national laboratory is adequate. In Ethiopia, coordinating surveillance and supplemental OPV vaccination activities with other countries of the Horn of Africa (i.e., Djibouti, Somalia, and Sudan) is important because of nomadic border populations. In July 2001, an internal surveillance review recommended targeting Nigerian states with continuing wild poliovirus transmission for conducting mop-up campaigns¹, conducting regular active AFP searches (especially in the riverine areas of the Niger-Delta area), and strengthening project management at national and zonal levels.

The substantial progress toward polio eradication in the four AFR priority countries underscores the feasibility of interrupting poliovirus. Future priorities for the region include 1) improving AFP surveillance to allow for better targeting of supplemental vaccination and mop-up activities, 2) reaching previously unvaccinated children and gaining access to all children in the four priority countries, 3) assuring an adequate supply of OPV vaccines for routine and supplemental vaccination activities, and 4) improving basic infrastructure for the Expanded Program on Immunization. Meeting these priorities will require continued external support.

References

- 1. CDC. Progress toward global poliomyelitis eradication, 1999. MMWR 2000;49:349-54.
- CDC. Progress toward poliomyelitis eradication—African Region, 1999–March 2000. MMWR 2000;49:445–9.
- 3. CDC. Progress toward poliomyelitis eradication—west and central Africa, 1999–2000. MMWR 2001;50:481–5.

[¶]Intensive house-to-house vaccination with OPV in high-risk districts, conducted in two rounds, 4–6 weeks apart.

Weekly Update: West Nile Virus Activity — United States, September 19–25, 2001

The following report summarizes West Nile virus (WNV) surveillance data reported to CDC through ArboNET and verified by states and other jurisdictions as of September 25, 2001.

During the week of September 19–25, eight human cases of WNV encephalitis were reported in Maryland (five) and New York (three); no deaths were reported. During the same period, WNV infections were reported in 430 crows, 76 other birds, and nine horses. A total of 57 WNV-positive mosquito pools were reported in five states (Connecticut, Illinois, Massachusetts, New Jersey, and Pennsylvania).

During 2001, 20 human cases of WNV encephalitis have been reported in New York (six), Maryland (five), Florida (four), Connecticut (three), Georgia (one), and New Jersey (one); one death occurred in Georgia. A total of 2521 crows and 952 other birds with WNV infection were reported from 23 states and the District of Columbia (Figure 1); 89 WNV infections in other animals (all horses) were reported from 10 states (Alabama, Connecticut, Florida, Georgia, Kentucky, Louisiana, Massachusetts, New York, Pennsylvania, and Virginia); and 568 WNV-positive mosquito pools were reported from 12 states (Connecticut, Florida, Georgia, Illinois, Maryland, Massachusetts, New Hampshire, New Jersey, New York, Ohio, Pennsylvania, and Rhode Island).

Additional information about WNV activity is available at http://cindi.usgs.gov/hazard/event/west_nile/west_nile.htm]




FIGURE 1. Areas reporting West Nile virus (WNV) activity — United States, 2001*

⁺ Kentucky reported WNV infection in a horse but no birds.

^{*} As of September 25, 2001.

Notice to Readers

Walk to School Day — October 2, 2001

October 2 has been designated International Walk to School Day. The goal of this event is to increase public awareness of the importance of regular physical activity for children, improve pedestrian safety, and create more walkable communities. This year, an estimated 20 countries and 49 states will participate by encouraging children to walk or bike to school in a safe, supportive environment.

CDC supports Walk to School Day and walking and biking to school year-long through the KidsWalk-to-School program, which is a part of CDC's Active Community Environments (ACEs) initiative. ACEs is exploring how policies and the design of new and existing communities can promote physical activity for recreation and utilitarian purposes. KidsWalk-to-School is a community-based program that encourages and promotes walking and biking to school. As part of the program, communities build partnerships with schools, local police, public works, politicians, businesses, and civic associations to create an environment that supports safe and active travel to school. The program was developed in response to low rates of walking, inadequate levels of physical activity, and a 50% increase in the proportion of children who are overweight since the late 1970s.

Many states are implementing walk-to-school efforts. For example, California is piloting Safe Routes to School Legislation, which allocates a percentage of TEA-21 federal highway funds to improve pedestrian safety near schools. Similar legislation is pending in Georgia, Maryland, and Montana.

CDC's KidsWalk-to-School information and materials are available at <http:// www.cdc.gov/nccdphp/dnpa/kidswalk.htm>. Information on Walk to School Day is available at <http://www.walktoschool-usa.org> and <http://www.iwalktoschool.org>.

Notice to Readers

Satellite Broadcast on HIV Prevention

"Update on CDC's Revised Guidelines for HIV Counseling, Testing, and Referral," a satellite broadcast, is scheduled for Thursday, November 15, 2001, from 1 p.m. to 3 p.m. eastern daylight time. CDC and the Public Health Training Network are co-sponsoring this forum, which will focus on why quality HIV counseling, testing, and referral are critical to prevention and care services, and on key recommendations of CDC's *Revised Guidelines for HIV Counseling, Testing, and Referral*. Presentations and interviews will provide an update on implementation issues for the updated guidelines. This broadcast is designed for policy developers and service providers of HIV counseling, testing, and referral. Viewers are invited to submit questions before and during the broadcast.

Additional information is available at <http://www.cdcnpin.org/broadcast> and through CDC's fax information system, telephone (888) 232-3299 ([888] CDC-FAXX]), by entering document number 130040 and a return fax number. Organizations setting up viewing sites are encouraged to register online or by fax as early as possible so that viewers can access information about viewing locations when visiting the Internet site or calling the information line.




FIGURE I. Selected notifiable disease reports, United States, comparison of provisional 4-week totals ending September 22, 2001, with historical data

- * No rubella cases were reported for the current 4-week period yielding a ratio for week 38 of zero (0).
- [†] Ratio of current 4-week total to mean of 15 4-week totals (from previous, comparable, and subsequent 4-week periods for the past 5 years). The point where the hatched area begins is based on the mean and two standard deviations of these 4-week totals.

		Cum.2001		Cum. 2001
Anthrax		-	Poliomyelitis, paralytic	-
Brucellosis [†]		57	Psittacosis [†]	10
Cholera		3	Q fever [†]	16
Cyclosporiasis [†]		113	Rabies, human	1
Diphtheria		2	Rocky Mountain spotted fever (RMSF)	380
Ehrlichiosis: human	granulocytic (HGE)†	143	Rubella, congenital syndrome	-
human	monocytic (HME) [†]	60	Streptococcal disease, invasive, group A	2,697
	nia serogroup viral [†]	46	Streptococcal toxic-shock syndrome [†]	45
	equine	5	Syphilis, congenital [¶]	166
St. Lou	ist	1	Tetanus	22
wester	n equine [†]	-	Toxic-shock syndrome	89
Hansen disease (lepros	sv)†	56	Trichinosis	15
Hantavirus pulmonary	svndrome [†]	5	Tularemia [†]	79
Hemolytic uremic syn		96	Typhoid fever	190
HIV infection, pediatrie	215	131	Yellow fever	-
Plaque		2		

TABLE I. Summary of provisional cases of selected notifiable diseases, United States, cumulative, week ending September 22, 2001 (38th Week)*

-: No reported cases. *Incidence data for reporting year 2001 are provisional and cumulative (year-to-date).

⁵ Updated monthly from reports to the Division of HIV/AIDS Prevention — Surveillance and Epidemiology, National Center for HIV,

STD, and TB Prevention (NCHSTP). Last update August 28, 2001. ¹Updated from reports to the Division of STD Prevention, NCHSTP.

	лі	DS	Chlan	nydia⁵	Crypton	poridiosis	NET	<i>Escherichia</i> ISS	<i>coli</i> О157:Н РН	7† ILIS
Demention - Aus	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.	Cum.
Reporting Area	2001 [¶] 25,869	2000 28,145	2001 490,605	2000 503,993	2001 1,910	2,038	2001 1,941	2000 3,388	2001 1,503	2,852
NEW ENGLAND Maine N.H. Vt. Mass. R.I. Conn.	996 26 27 11 541 72 319	1,531 25 27 29 998 61 391	15,978 754 932 433 6,868 2,131 4,860	16,875 1,046 791 386 7,134 1,903 5,615	84 13 8 27 29 3 4	101 17 15 20 29 2 18	181 24 28 11 89 10 19	303 24 29 28 140 11 71	168 26 21 8 77 8 28	315 25 31 30 143 14 72
MID. ATLANTIC Upstate N.Y. N.Y. City N.J. Pa.	5,634 697 2,742 1,194 1,001	6,389 610 3,478 1,249 1,052	55,475 9,852 20,641 8,393 16,589	46,609 1,194 19,148 8,106 18,161	192 80 68 7 37	268 71 138 14 45	148 109 8 31 N	342 215 21 106 N	122 85 8 29	239 42 14 106 77
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	1,922 367 225 882 328 120	2,581 389 250 1,365 437 140	74,314 14,908 10,174 19,427 21,461 8,344	86,989 22,927 9,556 24,254 18,425 11,827	683 135 60 1 124 363	694 171 41 87 74 321	512 138 57 114 67 136	834 194 96 161 108 275	318 97 32 80 62 47	610 182 72 129 92 135
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak. Nebr. Kans.	571 104 63 271 2 19 49 63	634 129 65 288 2 6 43 101	24,531 4,878 1,858 9,400 685 1,314 2,132 4,264	28,399 5,825 3,971 9,480 661 1,323 2,743 4,396	279 121 66 31 9 6 45 1	195 22 58 23 9 13 61 9	300 95 63 40 12 29 47 14	480 109 145 91 15 45 53 22	275 98 48 58 24 39 - 8	480 149 126 82 17 48 44 14
S. ATLANTIC Del. Md. D.C. Va. W. Va. N.C. S.C. Ga. Fla.	8,247 185 1,089 591 673 58 574 500 935 3,642	7,777 131 958 500 517 44 502 610 876 3,639	92,629 2,041 8,138 2,087 13,359 1,700 14,743 8,362 18,610 23,589	95,073 2,101 10,148 2,253 11,424 1,554 16,512 6,902 20,077 24,102	236 4 31 10 16 2 21 - 84 68	315 5 9 7 14 3 19 - 114 144	172 4 20 - 46 9 36 7 19 31	277 2 25 1 53 13 61 18 35 69	118 6 1 U 36 8 28 11 13 13	237 1 50 7 61 15 36 66
E.S. CENTRAL Ky. Tenn. Ala. Miss.	1,279 245 408 308 318	1,438 147 635 338 318	35,036 6,525 10,859 9,459 8,193	36,899 5,769 10,569 11,682 8,879	38 4 12 12 10	39 5 10 12 12	95 43 31 14 7	103 30 46 7 20	84 39 33 6 6	87 27 43 7 10
W.S. CENTRAL Ark. La. Okla. Tex.	2,836 144 602 172 1,918	2,956 149 445 259 2,103	71,134 5,291 12,410 7,662 45,771	75,795 4,862 13,354 6,421 51,158	25 6 7 10 2	121 9 10 10 92	46 7 3 19 17	202 54 13 13 122	60 25 20 15	250 37 41 13 159
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex. Ariz. Utah Nev.	955 14 17 2 197 84 395 84 162	1,059 10 16 7 257 116 318 98 237	28,153 1,455 1,332 601 5,284 4,193 10,284 1,454 3,550	28,645 1,022 1,335 570 8,277 3,557 9,476 1,569 2,839	145 25 13 4 30 19 6 44 4	112 10 5 53 12 10 11 3	210 16 46 5 71 11 22 28 11	312 27 48 14 118 17 37 41 10	118 - 1 63 8 21 24 1	240 31 9 85 16 31 58 10
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	3,429 371 134 2,871 15 38	3,780 332 113 3,227 15 93	93,355 9,573 5,362 73,737 1,940 2,743	88,709 9,417 4,926 69,955 1,818 2,593	228 37 35 152 1 3	193 U 14 179	277 65 44 147 4 17	535 172 111 213 26 13	240 62 37 137 - 4	394 176 100 105 3 10
Guam P.R. V.I. Amer. Samoa C.N.M.I.	10 816 2 -	13 869 26 -	1,847 53 U 96	354 U U U	- - - U	- - - U U	N 1 - U	N 6 - U U		U U U U

TABLE II. Provisional cases of selected notifiable diseases, United States, weeks ending September 22, 2001, and September 23, 2000 (38th Week)*

 N: Not notifiable.
 U: Unavailable.
 :: No reported cases.
 C.N.M.I.: Commonwealth of Northern Mariana Islands.

 * Incidence data for reporting year 2001 are provisional and cumulative (year-to-date). Incidence data for reporting year 2000 are finalized and cumulative (year-to-date).

 * Individual cases can be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the Public Health Laboratory Information System (PHLIS).

 * Individual cases to genital infections caused by *C. trachomatis*.

 * Updated monthly from reports to the Division of HIV/AIDS Prevention — Surveillance and Epidemiology, National Center for HIV, STD, and TB Prevention. Last update August 28, 2001.

	Gono	rrhea	Hepatit Non-A, N		Legione	llosis	Listeriosis		rme ease
Reporting Area	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2001	Cum. 2000
UNITED STATES	225,809	256,450	2,418	2,342	692	752	328	8,093	12,454
NEW ENGLAND Maine N.H. Vt. Mass. R.I. Conn.	4,529 86 128 50 2,090 591 1,584	4,793 62 77 48 1,965 461 2,180	14 - 6 8 -	23 2 4 12 5	38 5 8 5 9 4 7	41 2 4 15 4 14	35 - 3 2 17 1 12	2,280 104 12 484 341 1,339	3,956 51 27 1,032 307 2,539
MID. ATLANTIC Upstate N.Y. N.Y. City N.J. Pa.	27,794 5,990 8,627 5,127 8,050	27,274 5,163 8,228 5,326 8,557	1,194 44 1,107 43	527 27 - 465 35	137 43 13 7 74	204 55 30 17 102	52 22 8 10 12	4,274 2,258 2 783 1,231	6,455 2,621 155 2,231 1,448
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	40,245 8,275 4,300 12,161 12,592 2,917	52,051 13,952 4,487 15,292 13,236 5,084	129 8 1 12 108	182 9 - 18 155 -	182 94 15 - 48 25	201 82 29 25 33 32	41 13 4 1 18 5	447 98 17 1 331	693 47 20 33 21 572
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak. Nebr.	10,462 1,570 428 5,683 25 212 701	12,564 2,309 888 6,053 55 218 1,091	514 8 496 - - 3	420 5 1 403 - 4	43 9 6 18 1 3 5	46 3 12 22 - 2 3	11 - 1 6 - - 1	289 237 26 21 - - 3	236 150 24 44 1 - 3
Kans.	1,843	1,950	3 7	7	5 1	4	3	2	14
S. ATLANTIC Del. Md. D.C. Va. W. Va. N.C. S.C. Ga. Fla.	57,619 1,212 4,486 1,900 8,046 477 12,337 5,714 10,117 13,330	67,043 1,226 6,981 1,825 7,217 485 13,522 6,199 12,889 16,699	82 - - 9 16 5 - 39	72 2 10 3 14 13 2 3 22	149 5 30 7 18 N 7 9 9 64	138 8 45 3 25 N 12 4 6 35	53 - 9 5 2 4 10 14	643 33 415 8 102 10 32 4 - 39	913 167 533 4 120 26 39 5 - 19
E.S. CENTRAL Ky. Tenn. Ala. Miss.	22,642 2,553 7,322 7,367 5,400	26,589 2,536 8,443 9,015 6,595	163 8 52 3 100	349 30 73 7 239	44 9 21 12 2	25 14 8 2 1	16 4 7 5	41 18 14 8 1	42 8 26 5 3
W.S. CENTRAL Ark. La. Okla. Tex.	34,990 3,229 8,543 3,495 19,723	39,976 2,842 9,840 2,797 24,497	165 3 78 3 81	570 7 321 7 235	5 - 2 3 -	21 - 7 2 12	6 1 - 2 3	7 - 1 - 6	64 5 7 52
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex. Ariz. Utah Nev.	7,191 83 59 2,054 679 2,829 116 1,314	7,692 31 64 39 2,329 796 3,178 162 1,093	54 1 2 6 17 11 9 2 6	59 4 3 2 12 12 14 - 12	38 - 1 12 2 11 7 3	28 1 4 10 1 7 5	28 - 1 6 6 6 2 6	12 - 6 1 - - 2 2	7 - 1 3 - - 1 2
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	20,337 2,137 834 16,630 300 436	18,468 1,651 683 15,538 251 345	103 17 12 74	140 24 23 91 - 2	56 7 N 45 - 4	48 14 N 33 - 1	86 7 5 68 - 6	100 7 6 85 2 N	88 7 72 2 N
Guam P.R. V.I. Amer. Samoa C.N.M.I.	430 6 U 9	39 382 - U U	- 1 Ū	2 1 - U U	2 - U	- 1 - U U	- - -	N Ū	- N - U U

TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United States,
weeks ending September 22, 2001, and September 23, 2000 (38th Week)*

N: Not notifiable. U: Unavailable. - : No reported cases. * Incidence data for reporting year 2001 are provisional and cumulative (year-to-date). Incidence data for reporting year 2000 are finalized and cumulative (year-to-date).

		•		•	Salmonellosis [†]						
	Ma	laria	Rabies	s, Animal		TSS		HLIS			
Reporting Area	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000			
UNITED STATES	838	1,060	4,661	5,243	24,638	28,040	20,150	24,164			
NEW ENGLAND Maine N.H. Vt. Mass. R.I. Conn.	49 4 1 19 6 17	57 5 1 2 27 6 16	523 52 19 51 194 48 159	605 100 9 47 208 44 197	1,697 145 141 61 1,011 88 251	1,707 98 103 96 996 106 308	1,621 134 120 63 801 133 370	1,742 77 102 93 1,003 123 344			
MID. ATLANTIC Upstate N.Y. N.Y. City N.J. Pa.	211 50 105 25 31	277 48 159 40 30	932 594 22 155 161	968 608 8 142 210	3,069 882 750 651 786	3,715 881 939 917 978	2,594 816 830 527 421	3,994 997 1,004 786 1,207			
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	79 21 14 1 29 14	111 15 54 25 12	110 42 3 22 37 6	136 45 - 20 60 11	3,564 1,065 398 886 605 610	3,933 1,008 466 1,211 672 576	3,020 991 354 704 610 361	2,646 1,117 481 1 734 313			
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak. Nebr. Kans.	29 6 5 11 - 2 5	43 13 2 12 2 - 8 6	266 32 65 36 33 25 4 71	441 69 64 43 100 79 1 85	1,539 399 238 444 43 116 117 182	1,795 415 269 533 48 74 173 283	1,646 474 222 620 66 108 - 156	1,971 544 267 641 63 87 124 245			
S. ATLANTIC Del. Md. D.C. Va. W. Va. N.C. S.C. Ga. Fla.	229 1 99 13 41 1 12 6 12 44	233 4 78 14 44 2 23 2 16 50	1,673 30 243 324 111 445 91 271 158	1,775 39 321 - 90 436 118 218 122	6,264 61 627 60 1,060 96 932 605 949 1,874	5,607 84 591 42 743 124 766 537 1,019 1,701	4,310 84 652 U 747 100 905 532 918 372	4,420 103 534 U 706 116 829 421 1,312 399			
E.S. CENTRAL Ky. Tenn. Ala. Miss.	29 12 10 5 2	37 14 9 13 1	167 21 90 54 2	154 18 80 55 1	1,784 271 450 520 543	1,677 293 427 471 486	1,281 143 566 409 163	1,334 202 609 432 91			
W.S. CENTRAL Ark. La. Okla. Tex.	10 3 4 2 1	64 3 10 7 44	515 20 53 442	700 20 3 48 629	1,721 589 274 312 546	3,538 497 594 291 2,156	1,434 92 566 265 511	2,141 415 481 226 1,019			
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex. Ariz. Utah Nev.	40 2 3 - 18 3 5 4 5	38 1 3 - 20 - 6 4 4	201 31 20 - 13 103 12 1	217 55 9 46 - 18 74 9 6	1,563 59 108 48 420 204 436 179 109	2,042 70 92 51 556 180 515 369 209	1,216 4 3399 158 453 136 23	1,950 90 44 540 171 554 373 178			
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	162 5 10 137 1 9	200 23 32 135 - 10	274 2 235 37	247 - 7 215 25 -	3,437 371 180 2,569 32 285	4,026 400 229 3,183 42 172	3,028 491 244 2,052 2 239	3,966 509 289 2,959 30 179			
Guam P.R. V.I. Amer. Samoa C.N.M.I. N: Not notifiable.	3 - U -	2 4 Ū U	71 - U -	59 U U	426 U 10	21 474 Ū U	U U U U	U U U U U			

TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United States,
weeks ending September 22, 2001, and September 23, 2000 (38th Week)*

N: Not notifiable. U: Unavailable. -: No reported cases. * Incidence data for reporting year 2001 are provisional and cumulative (year-to-date). Incidence data for reporting year 2000 are finalized and cumulative (year-to-date). * Individual cases can be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the Public Health Laboratory Information System (PHLIS).

		Shige	llosis [†]	.,	r	philis			
L L	NET			HLIS	(Primary 8	Secondary)		rculosis	
Reporting Area	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	
UNITED STATES	11,895	16,161	5,613	9,209	4,037	4,391	8,476	10,181	
NEW ENGLAND Maine N.H. Vt. Mass. R.I. Conn.	205 6 4 7 145 16 27	308 9 4 223 22 46	183 2 5 116 20 38	301 11 7 205 25 53	39 - 1 2 20 8 8 8	61 1 - 43 4 12	301 7 11 2 170 27 84	300 12 15 4 176 27 66	
MID. ATLANTIC Upstate N.Y. N.Y. City N.J. Pa.	1,012 402 265 185 160	2,043 585 814 429 215	583 93 268 157 65	1,313 179 559 368 207	340 21 176 86 57	203 7 90 48 58	1,690 238 865 371 216	1,651 221 889 388 153	
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	3,173 2,259 166 296 235 217	3,320 274 1,262 954 563 267	1,386 969 29 204 163 21	920 228 135 2 511 44	681 58 124 200 281 18	904 58 273 315 217 41	907 163 73 432 185 54	979 210 96 454 153 66	
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak. Nebr. Kans.	1,228 296 325 245 20 229 56 57	1,769 578 386 536 14 5 91 159	994 341 265 146 23 188 - 31	1,508 658 269 378 37 37 3 72 91	55 22 1 13 - 2 17	53 11 10 25 - 2 5	321 166 18 97 3 10 27	366 116 27 136 2 14 17 54	
S. ATLANTIC Del. Md. D.C. Va. W. Va. N.C. S.C. Ga. Fla.	1,765 12 115 43 230 8 279 206 182 690	2,053 16 147 57 335 4 152 99 188 1,055	584 10 67 U 124 8 143 107 91 34	871 17 86 U 261 3 203 74 143 84	1,426 9 170 35 83 - 335 185 252 357	1,464 8 221 30 100 3 382 156 280 284	1,704 15 51 184 22 249 134 317 575	2,041 14 188 21 196 22 271 205 458 666	
E.S. CENTRAL Ky. Tenn. Ala. Miss.	1,033 376 76 180 401	761 294 266 48 153	403 175 77 124 27	406 57 305 39 5	453 34 245 90 84	635 62 385 92 96	551 78 207 188 78	687 83 262 230 112	
W.S. CENTRAL Ark. La. Okla. Tex.	1,094 431 117 43 503	2,543 157 211 85 2,090	720 155 137 16 412	790 43 133 32 582	497 27 116 50 304	601 77 169 88 267	714 102 100 512	1,500 148 135 113 1,104	
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex. Ariz. Utah Nev.	693 4 27 3 163 95 294 48 59	841 7 42 5 182 105 331 63 106	468 - 1 163 58 197 41 8	600 25 3 143 71 223 69 66	175 1 31 16 114 7 5	167 - 1 7 14 139 1 4	344 6 8 3 78 21 151 26 51	377 10 6 2 61 33 157 32 76	
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	1,692 146 62 1,426 5 53	2,523 355 132 2,001 7 28	292 167 78 - 1 46	2,500 337 93 2,041 3 26	371 37 11 313 10	303 50 10 242 - 1	1,944 175 79 1,553 36 101	2,280 179 72 1,850 81 98	
Guam P.R. V.I. Amer. Samoa	- 8 - U	34 28 - U		U U U U	172 - U	3 123 Ū	- 76 - U	39 109 Ū	
C.N.M.I.	4 	Ŭ	Ŭ		3	Ŭ	22	Ŭ	

TABLE II. (Cont'd) Provisional cases of selected notifiable diseases, United States, weeks ending September 22, 2001, and September 23, 2000 (38th Week)*

N: Not notifiable. U: Unavailable. -: No reported cases. * Incidence data for reporting year 2001 are provisional and cumulative (year-to-date). Incidence data for reporting year 2000 are finalized and cumulative (year-to-date). † Individual cases can be reported through both the National Electronic Telecommunications System for Surveillance (NETSS) and the Public Health Laboratory Information System (PHLIS).

	H. influ	ienzae,	ina Sep н	epatitis (Vi					Measles (Rubeola)				
		sive	Α		В		Indige		Impo		Tota		
Reporting Area	Cum. 2001 [§]	Cum. 2000	Cum. 2001	Cum. 2000	Cum. 2001	Cum. 2000	2001	Cum. 2001	2001	Cum. 2001	Cum. 2001	Cum. 2000	
UNITED STATES	979	933	6,872	9,502	4,725	5,076	1	49	-	42	91	71	
NEW ENGLAND Maine	59 1	74 1	404 9	288 14	67 5	82 5	-	4	-	1	5	6	
N.H. Vt.	4 3	12 7	12 8	18 8	12 4	14 6	-	- 1	-	-	- 1	3 3	
Mass.	35	35	160	110	2	12	-	2	-	1	3	-	
R.I. Conn.	3 13	4 15	29 186	19 119	20 24	14 31	-	- 1	-	-	- 1	-	
MID. ATLANTIC	146	174	700	1,078	791	871	-	4	-	11	15	21	
Upstate N.Y. N.Y. City	56 36	72 47	181 209	163 370	103 322	90 428	-	1 2	-	4 1	5 3	10 10	
N.J. Pa.	38 16	32 23	159 151	211 334	168 198	138 215	-	- 1	-	1 5	1 6	- 1	
E.N. CENTRAL	131	146	760	1,250	661	528	-	-	-	10	10	7	
Ohio Ind.	53 39	44 26	181 74	210 73	86 36	86 39	-	-	-	3 4	3 4	2	
III. Mich.	10 7	48 9	212 247	546 353	113 426	90 290	-	-	-	3	3	3 2	
Wis.	22	19	46	68	-	230	-	-	-	-	-	-	
W.N. CENTRAL Minn.	51 30	56 29	309 30	568 161	141 16	219 30	-	4 2	-	-	4 2	1 1	
lowa Mo.	13	17	28 86	59 230	19 73	26 107	-	- 2	-	-	- 2	-	
N. Dak.	6	2	2	3	-	2	-	-	-	-	-	-	
S. Dak. Nebr.	- 1	1 3	2 29	1 26	1 17	1 32	Ū	-	Ū	-	-	-	
Kans.	1	4	132	88	15	21	-	-	-	-	-	-	
S. ATLANTIC Del.	289	207	1,709	1,031 11	1,006	888 10	-	4	-	1 -	5	3	
Md. D.C.	68 -	60	199 33	157 20	108 11	97 27	- U	2	Ū	1	3	-	
Va. W. Va.	21 14	33 6	101 10	116 52	124 20	120 10	-	1	-	-	1	2	
N.C. S.C.	41 5	19 7	152 62	114 48	149 24	182 13	-	-	-	-	-	-	
Ga.	69	52	661	189	244	155	-	1	-	-	1	-	
Fla. E.S. CENTRAL	71 62	30 39	491 293	324 323	326 321	274 354	-	- 2	-	-	- 2	1	
Ky.	2	12	98	41	32	62	-	2	-	-	2	-	
Tenn. Ala.	32 26	16 9	112 67	112 43	172 63	165 44	-	-	-	-	-	-	
Miss.	2	2	16	127	54	83	-	-	-	-	-	-	
W.S. CENTRAL Ark.	36	58 2	645 59	1,828 115	475 71	809 75	-	1 -	-	-	1 -	-	
La. Okla.	3 33	16 38	54 99	66 199	30 69	111 113	-	-	-	-	-	-	
Tex.	-	2	433	1,448	305	510	U	1	U	-	1	-	
MOUNTAIN Mont.	116	90 1	589 10	673 5	395 3	383 6	1	2	-	1	3	12	
Idaho Wyo.	1	3 1	50 6	19 4	10 2	6 2	1	1	-	1	2	-	
Colo. N. Mex.	29 18	22 18	67 30	156 60	83 119	64 110	-	-	-	-	-	2	
Ariz.	52	35 7	317	339	121	143	-	1	-	-	- 1	-	
Utah Nev.	6 10	3	63 46	41 49	25 32	17 35	Ū	-	Ū	-	-	3 7	
PACIFIC	89	89	1,463	2,463	868	942		28	-	18	46	21	
Wash. Oreg.	2 17	5 26	98 64	216 146	100 72	76 82	U -	13 3	U -	2	15 3	3	
Calif. Alaska	42 6	30 6	1,286 14	2,077 11	672 9	765 9	-	10	-	11 -	21	14 1	
Hawaii	22	22	1	13	15	10	-	2	-	5	7	3	
Guam P.R.	- 1	1 3	- 80	1 203	- 131	9 208	U -	-	U -	-	-	- 2	
V.I. Amer. Samoa	Ū	Ū	Ū	Ū	Ū	Ū	U U	Ū	U U	Ū	Ū	Ū	
C.N.M.I.	-	Ŭ	-	Ŭ	28	Ŭ	Ŭ	-	Ŭ	-	-	Ŭ	

TABLE III. Provisional cases of selected notifiable diseases preventable by vaccination, United States, weeks ending September 22, 2001, and September 23, 2000 (38th Week)*

N: Not notifiable.
U: Unavailable.
·: No reported cases.
* Incidence data for reporting year 2001 are provisional and cumulative (year-to-date). Incidence data for reporting year 2000 are finalized and cumulative (year-to-date).

* For imported measles, cases include only those resulting from importation from other countries.
* Of 252 cases among children aged <5 years, serotype was reported for 100, and of those, 17 were type b.

		jococcal ease		Mumps			Pertussis	,		Rubella	
Reporting Area	Cum. 2001	Cum. 2000	2001	Cum. 2001	Cum. 2000	2001	Cum. 2001	Cum. 2000	2001	Cum. 2001	Cum. 2000
UNITED STATES	1,635	1,660	1	159	264	51	3,273	4,779	-	17	123
NEW ENGLAND Maine N.H. Vt.	89 2 12 5	100 8 11 2	- - -		4 - - -	1 - 1 -	279 - 26 26	1,200 33 83 181	- - -	- - -	12 - 2 -
Mass. R.I. Conn.	49 3 18	56 8 15	-	- -	1 1 2	- - -	208 5 14	850 14 39	- - -	- -	8 1 1
MID. ATLANTIC Upstate N.Y. N.Y. City N.J. Pa.	168 46 31 40 51	186 52 36 35 63	- - - -	18 3 9 2 4	20 7 6 3 4	- - - -	230 118 34 13 65	465 201 68 30 166		5 1 3 1	9 1 8 - -
E.N. CENTRAL Ohio Ind. III. Mich. Wis.	219 75 33 22 49 40	291 70 32 70 84 35	- - - -	15 1 1 11 2 -	19 7 1 6 4 1	20 11 5 2 2	469 246 61 57 51 54	565 263 75 68 60 99	- - - -	3 - 1 2 -	1 - - 1 -
W.N. CENTRAL Minn. Iowa Mo. N. Dak. S. Dak. Nebr.	113 16 21 41 5 5 12	117 17 25 55 2 5 6	- - - - U	7 3 - - - 1	16 - 7 4 1 - 1	- - - - U	187 70 19 75 - 3 4	368 215 44 50 3 3 21	- - - - U	3 - 1 - - -	1 - - - 1
Kans.	13	7	-	3	3	-	16	32	-	1	-
S. ATLANTIC Del. Md. D.C.	308 4 36	231 - 26	- - - U	28 - 5 -	38 - 9 -	6 - 2 U	182 - 29 1	352 8 87 3	- - - U	4 - -	72 - -
Va. W. Va. N.C. S.C. Ga. Fla.	33 11 59 31 36 98	35 11 32 19 38 70		6 - 3 2 7 5	8 - 5 10 2 4	3 - - - - 1	35 2 51 32 7 25	66 1 77 23 34 53	-	- - 2 - 2	- 64 6 - 2
E.S. CENTRAL Ky. Tenn. Ala. Miss.	112 19 50 30 13	114 25 45 31 13	1 - 1 -	6 1 - 4	5 1 2 2	4 - 2 2 -	93 19 41 29 4	92 45 27 17 3			6 1 1 4
W.S. CENTRAL Ark. La. Okla. Tex.	178 17 56 25 80	173 11 40 23 99	- - - U	9 1 2 - 6	28 1 5 - 22	5 - 5 U	270 12 2 6 250	284 33 18 16 217	- - - U		8 1 1 - 6
MOUNTAIN Mont. Idaho Wyo. Colo. N. Mex.	79 4 7 5 27 12	73 4 6 25 6	- - - -	9 1 1 1 2	17 1 - 1 - 1	10 - - 5 5	1,081 31 167 1 210 111	565 33 51 4 310 79		1 - - 1 -	2 - - 1 -
Ariz. Utah Nev.	12 7 5	22 7 3	- - U	1 1 1	4 4 6	- - U	491 59 11	62 16 10	- - U	- -	1 - -
PACIFIC Wash. Oreg. Calif. Alaska Hawaii	369 53 32 271 2 11	375 40 51 268 8 8	U N -	67 1 30 1 35	117 9 N 80 8 20	5 U 5 - -	482 110 42 298 3 29	888 282 95 461 18 32	U - - -	1 - - - 1	12 7 5 -
Guam P.R. V.I.	- 4 -	- 8 -	U Ū	-	12 - -	U - U	2	3 6 -	U - U	- -	1 - -
Amer. Samoa C.N.M.I.	U -	U U	U U	U -	U U	U U	U -	U U	U U	U -	U U

TABLE III. (Cont'd) Provisional cases of selected notifiable diseases preventable by vaccination, United States, weeks ending September 22, 2001, and September 23, 2000 (38th Week)*

N: Not notifiable. U: Unavailable. -: No reported cases. * Incidence data for reporting year 2001 are provisional and cumulative (year-to-date). Incidence data for reporting year 2000 are finalized and cumulative (year-to-date).

		All Cau	ises, By	Age (Ye			P&I [†]	2001 (Soth V		All Cau	ses, By	Age (Y	ears)		P&I [†]
Reporting Area	All Ages	≥ 65	45-64	25-44	1-24	<1	Total	Reporting Area	All Ages	≥65	45-64	25-44	1-24	<1	Total
NEW ENGLAND Boston, Mass. Bridgeport, Conn Cambridge, Mass Fall River, Mass. Hartford, Conn. Lowell, Mass. Lynn, Mass. New Bedford, Ma New Haven, Conr Providence, R.I. Somerville, Mass Springfield, Mass	. 21 35 48 23 11 1ss. 22 1. 30 63 . 4 5. 33	418 92 23 15 30 36 19 9 17 27 46 4 25	30 8 2 3 9 3 2 3 2 3 2 3 2 3 2 3 2 3 2 3 2 3	32 10 2 4 2 3 1 - 2 - 1 - 2	6 4 - - - 1 1 -	8 2 - - - - - 2 3	50 16 2 2 4 - - 2 1 2 - 3	S. ATLANTIC Atlanta, Ga. Baltimore, Md. Charlotte, N.C. Jacksonville, Fla Miami, Fla. Norfolk, Va. Richmond, Va. Savannah, Ga. St. Petersburg, Tampa, Fla. Washington, D. Wilmington, De	120 34 71 59 Fla. 59 175 C. 100	798 106 107 74 107 68 24 41 41 41 41 55 12	293 43 55 43 5 25 43 5 21 12 3 42 3 34 23 3	107 17 14 11 7 13 2 4 4 7 15 13	45 5 7 6 4 2 2 1 3 6 9 -	24 1 3 6 3 3 1 3 1 - 3 -	94 1 21 13 12 11 - 2 6 8 17 3
Waterbury, Conn Worcester, Mass. MID. ATLANTIC Albany, N.Y. Allentown, Pa. Buffalo, N.Y. Camden, N.J. Elizabeth, N.J. Erie, Pa.§ LorowCitt, N.J.	59 991 48 12 80 32 24 36	25 50 699 41 9 59 21 18 29	4 196 5 3 16 6 4 4	1 4 62 1 - 5 2 2 2 2	- 17 1 - 2 -	- 16 - - 1 - 1	4 14 69 5 - 11 2 -	E.S. CENTRAL Birmingham, Al Chattanooga, Te Knoxville, Tenn. Lexington, Ky. Memphis, Tenn Mobile, Ala. Montgomery, A Nashville, Tenn.	enn. 77 108 46 . 159 105 .la. 35	534 95 50 75 29 106 71 23 85	169 35 22 21 11 34 22 7 17	56 8 7 12 8 2 14	18 4 4 4 1 1 3 1	17 4 - 1 2 6 3 - 1	57 12 5 9 5 10 4 2 10
Jersey City, N.J. New York City, N. Paterson, N.J. Philadelphia, Pa. Pittsburgh, Pa.§ Reading, Pa. Rochester, N.Y. Scranton, Pa.§ Syracuse, N.Y. Trenton, N.J. Utica, N.Y. Yonkers, N.Y.	U 16 319 38 24 128	32 U U 194 24 17 104 13 25 68 215 0 U	UU4838518431581	2 U U 2 5 2 2 5 2 2 5 2 U U	1 U 9 3 - - - - U	U U 7 2 - 5 - U	- UU - 15 1 1 12 3 1 14 3 1 U	W.S. CENTRAL Austin, Tex. Baton Rouge, La Corpus Christi, Dallas, Tex. El Paso, Tex. Ft. Worth, Tex. Houston, Tex. Little Rock, Ark. New Orleans, La Shreveport, La. Tulsa, Okla.	Tex. 55 188 116 119 376 42 1. U	959 52 29 41 102 83 70 231 28 U 155 76 92	340 27 12 5 49 22 33 101 9 U 44 19 19	113 11 6 7 19 5 10 33 2 U 14 4 2	48 32 - 12 4 3 7 3 U 5 5 4	27 1 2 6 2 3 4 - U 3 2 3	88 8 3 2 8 4 5 17 - U 14 13 14
E.N. CENTRAL Akron, Ohio Canton, Ohio Chicago, Ill. Cincinnati, Ohio Cleveland, Ohio Columbus, Ohio Dayton, Ohio Detroit, Mich. Evansville, Ind. Fort Wayne, Ind.	1,633 44 35 U 100 135 170 133 181 38 74	1,088 31 29 05 78 119 87 94 29 59	7 5 U 17 24 31 38 63 8 7	115 4 U 11 21 12 6 18 1 4	37 1 U 3 9 3 - 2 3	47 1 4 3 5 2 4 - 1	112 3 5 7 10 11 10 4 1	MOUNTAIN Albuquerque, N Boise, Idaho Colo. Springs, C Denver, Colo. Las Vegas, Nev. Ogden, Utah Phoenix, Ariz. Pueblo, Colo. Salt Lake City, L Tucson, Ariz.	41 Colo. 72 101 189 30 144 29 Jtah 98 140	720 119 32 51 62 139 22 87 23 74 111	165 25 7 12 22 31 5 29 4 13 17	73 11 2 6 12 14 2 12 1 5 8	24 6 - 1 2 1 8 - 1 4	23 - 2 4 3 - 8 1 5 -	66 12 4 4 14 14 7 2 7 11
Gary, Ind. Grand Rapids, Mi Indianapolis, Ind. Lansing, Mich. Milwaukee, Wis. Peoria, III. Rockford, III. South Bend, Ind. Toledo, Ohio Youngstown, Ohi	203 61 102 37 60 39 97 59	7 39 132 43 67 31 36 28 67 47	8 44 11 22 6 17 8 19 9	2 13 4 8 - 2 3 4 2	5 4 - 2 - 1 - 2 1	2 10 3 4 5	4 23 1 7 5 4 1 9 2	PACIFIC Berkeley, Calif. Fresno, Calif. Glendale, Calif. Honolulu, Hawa Long Beach, Cal Los Angeles, Ca Pasadena, Calif. Portland, Oreg. Sacramento, Ca	lif. 72 lif. 575 16 162 lif. 188	1,310 14 74 31 57 56 384 13 106 130	35	154 - 14 5 4 53 - 14 13	37 - 4 - 1 - 14 - 1 6 2	36 - 4 - 2 8 1 2 4	138 2 4 6 3 7 33 2 7 25
W.N. CENTRAL Des Moines, Iowa Duluth, Minn. Kansas City, Kans Kansas City, Mo. Lincoln, Nebr. Minneapolis, Mir Omaha, Nebr. St. Louis, Mo. St. Paul, Minn. Wichita, Kans.	29 . U 87 40	422 28 23 U 88 33 111 60 49 50 U	2 2 U 14 5 39 26 15 15	34 1 U 3 2 9 4 7 7 U	14 - U 1 - 5 1 4 2 U	18 2 U 1 3 3 5 U	37 6 3 U 5 2 10 4 7 U	San Diego, Cali San Francisco, (San Jose, Calif Santa Cruz, Cali Seattle, Wash. Spokane, Wash Tacoma, Wash. TOTAL	Calif. U 170 f. 25 109	130 U 119 23 65 41 67 6,948	30 U 31 24 11 14 2,071	11 U 12 - 14 9 746	2 U 3 - 2 1 3 246	4 U 5 - 4 2 - 216	14 U 10 4 12 4 5 711

C_{a} to the height $20, 2004, (204h)$ (Marak)	۱g
September 22, 2001 (38th Week)	

U: Unavailable. -:No reported cases. * Mortality data in this table are voluntarily reported from 122 cities in the United States, most of which have populations of ³100,000. A death is reported by the place of its occurrence and by the week that the death certificate was filed. Fetal deaths are not included. [†] Pneumonia and influenza. [§] Because of changes in reporting methods in this Pennsylvania city, these numbers are partial counts for the current week. Complete counts will be available in 4 to 6 weeks. [§] Total includes unknown ages.

Contributors to the Production of the MMWR (Weekly)

Weekly Notifiable Disease Morbidity Data and 122 Cities Mortality Data

Samuel L. Groseclose, D.V.M., M.P.H. Wayne S. Brathwaite

State Support Team Robert Fagan Jose Aponte Gerald Jones David Nitschke Scott Noldy Jim Vaughan Carol A. Worsham **CDC Operations Team** Carol M. Knowles Deborah A. Adams Willie J. Anderson Lateka M. Dammond Patsy A. Hall Mechele A. Hester Felicia J. Connor Pearl Sharp

Informatics

T. Demetri Vacalis, Ph.D. Michele D. Renshaw Eri

Erica R. Shaver

All *MMWR* references are available on the Internet at <http://www.cdc.gov/mmwr/>. Use the search function to find specific articles.

Use of trade names and commercial sources is for identification only and does not imply endorsement by the U.S. Department of Health and Human Services.

References to non-CDC sites on the Internet are provided as a service to *MMWR* readers and do not constitute or imply endorsement of these organizations or their programs by CDC or the U.S. Department of Health and Human Services. CDC is not responsible for the content of pages found at these sites.

The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format and on a paid subscription basis for paper copy. To receive an electronic copy on Friday of each week, send an e-mail message to *listserv@listserv.cdc.gov*. The body content should read SUBscribe mmwr-toc. Electronic copy also is available from CDC's World-Wide Web server at http://www.cdc.gov/mmwr or from CDC's file transfer protocol server at http://ftp.cdc.gov/pub/Publications/mmwr. To subscribe for paper copy, contact Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone (202) 512-1800.

Data in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Address inquiries about the *MMWR* Series, including material to be considered for publication, to: Editor, *MMWR* Series, Mailstop C-08, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333; telephone (888) 232-3228.

All material in the *MMWR* Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

Director, Centers for Disease Control and Prevention Jeffrey P. Koplan, M.D., M.P.H.	Director, Epidemiology Program Office Stephen B. Thacker, M.D., M.Sc.	Writers-Editors, <i>MMWR</i> (Weekly) Jill Crane David C. Johnson				
Deputy Director for Science and Public Health, Centers for Disease Control and Prevention David W. Fleming, M.D.	Editor, <i>MMWR</i> Series John W. Ward, M.D. Acting Managing Editor, <i>MMWR</i> (Weekly) Teresa F. Rutledge	Desktop Publishing Lynda G. Cupell Morie M. Higgins				
☆U.S. Government Printing Office: 2001-633-173/49013 Region IV						

Centers for Disease Control and Prevention (CDC) Atlanta, Georgia 30333 **Official Business** Penalty for Private Use \$300 Return Service Requested

HEALTH AND HUMAN SERVICES

DEPARTMENT OF

FIRST-CLASS MAIL POSTAGE & FEES PAID PHS/CDC Permit No. G-284

The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC) and is available free of charge in electronic format and on a paid subscription basis for paper copy. To receive an electronic copy on Friday of each week, send an e-mail message to *listserv@listserv.cdc.gov*. The body content should read SUBscribe mmwr-toc. Electronic copy also is available from CDC's World-Wide Web server at http://www.cdc.gov/mmwr or from CDC's file transfer protocol server at http://ftp.cdc.gov/pub/Publications/mmwr. To subscribe for paper copy, contact Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402; telephone (202) 512-1800.

Data in the weekly *MMWR* are provisional, based on weekly reports to CDC by state health departments. The reporting week concludes at close of business on Friday; compiled data on a national basis are officially released to the public on the following Friday. Address inquiries about the *MMWR* Series, including material to be considered for publication, to: Editor, *MMWR* Series, Mailstop C-08, CDC, 1600 Clifton Rd., N.E., Atlanta, GA 30333; telephone (888) 232-3228.

All material in the *MMWR* Series is in the public domain and may be used and reprinted without permission; citation as to source, however, is appreciated.

Director, Centers for Disease	Director,	Writers-Editors, <i>MMWR</i> (Weekly)
Control and Prevention	Epidemiology Program Office	Jill Crane
Jeffrey P. Koplan, M.D., M.P.H.	Stephen B. Thacker, M.D., M.Sc.	David C. Johnson
Deputy Director for Science and Public Health, Centers for Disease Control and Prevention David W. Fleming, M.D.	Editor, <i>MMWR</i> Series John W. Ward, M.D. Acting Managing Editor, <i>MMWR</i> (Weekly) Teresa F. Rutledge	Desktop Publishing Lynda G. Cupell Morie M. Higgins

☆U.S. Government Printing Office: 2001-633-173/49013 Region IV

Official Business Penalty for Private Use \$300 Return Service Requested

> PRESORTED STANDARD POSTAGE & FEES PAID GPO Permit No. G-26

SUPERINTENDENT OF DOCUMENTS

Washington, D.C. 20402

UNITED STATES GOVERNMENT PRINTING OFFICE